Please assess the completion status of the following clinical trial:

Trial Title: Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Applicable disease and eligible for myeloablative SCT~* Patients must have two partially HLA-matched CBUs~* Back-up stem cell source~* Adequate Karnofsky Performance score or Lansky Play-Performance scale~* Sufficient physiological reserves~* Signed written informed consent~Exclusion Criteria:~* HLA-matched donor able to donate~* Prior allogeneic HSCT~* Other active malignancy~* Active or uncontrolled infection~* Active/symptoms of central nervous system (CNS) disease~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- NiCord® (Type: EXPERIMENTAL): NiCord® is a stem/progenitor cell based product composed of ex vivo expanded allogeneic UCB cells.

Based on this trial design, predict the completion outcome and termination type (if applicable).